Blue Earth Therapeutics Secures $76.5 Million in Funding
Blue Earth Therapeutics Ltd, a pioneering company based in Oxford, UK, recently celebrated a significant milestone by successfully closing a Series A financing round, securing a total of $76.5 million. This impressive funding round was led by Soleus Capital, with Sands Capital Management playing a co-leading role. Additionally, the existing investor Bracco Imaging SpA participated in this financing, alongside new institutional investors including Woodline Partners and PBM Capital. This influx of capital will provide essential support for the company's ongoing efforts to advance its clinical-stage PSMA-targeted radioligand therapies, which aim to benefit patients in need of innovative cancer treatments.
Under the leadership of CEO David Gauden, Blue Earth Therapeutics is dedicated to developing the next generation of targeted radiotherapeutics.
The company is strategically focused on creating therapies specifically designed to treat patients battling cancer. Having been incubated within the Bracco family of companies, Blue Earth Therapeutics boasts a strong management team with deep expertise in the fields of radiopharmaceuticals and oncology drug development. This team is also well-versed in the fast-paced environment of biotechnology startups, positioning them to innovate and enhance current technologies while rapidly advancing new targeted therapies for serious medical conditions.
The emerging pipeline of Blue Earth Therapeutics is initially concentrating on prostate cancer, a significant area of need within oncology. The recent funding will not only allow the company to refine its existing pipeline but also drive the development of new therapies that could make a substantial impact in the lives of cancer patients. With David Canner from Soleus Capital and Michael Ginder from Sands Capital Management joining the Board of Directors alongside representatives from Bracco Imaging SpA and industry veteran David Gauden, Blue Earth Therapeutics is poised for continued growth and innovation in the challenging landscape of cancer treatment.
They've invested in Blue Earth Therapeutics
Get to know these Healthtech investors
| # | Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|---|
1 |  Soleus Capital | 1 investment(s) investment(s) | more info | |||
2 |  Sands Capital Management | 1 investment(s) investment(s) | more info | |||
3 |  Bracco Imaging SpA | investment(s) investment(s) | more info | |||
4 |  Woodline Partners | 1 investment(s) investment(s) | more info | |||
5 |  PBM Capital | 1 investment(s) investment(s) | more info |
Click here for a full list of 6,908+ startup investors in the UK